Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the ...
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform.
Press Release4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 ...
The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating to ...
Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates ...
Araris is advancing three preclinical candidates for the treatment of hematological and solid tumors developed using its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback